Search
Benzhydrocodone
go.drugbank.com/drugs/DB15465Approved[L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse. … It was first approved by the FDA in February 2018 in combination with [acetaminophen] under the trade name Apadaz, marketed by KVK Tech and developed by KemPharm.[L7859,L7862]
Botulinum toxin type A
go.drugbank.com/drugs/DB00083ApprovedInvestigationalIn 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. … [A231819,L32569] A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm
Ezogabine
go.drugbank.com/drugs/DB04953ApprovedWithdrawnIt is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures … in adult patients with refractory epilepsy.
Synonyms: N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester, N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl esterTriamterene
go.drugbank.com/drugs/DB00384Approved[L6163] Triamterene was approved by the Food and Drug Administration in the U.S. in 1964. … [L6163] Currently, triamterene is used in the treatment of edema associated with various conditions as monotherapy and is approved for use with other diuretics to enhance diuretic and potassium-sparing
Mixtures: TRIAMETERENO E HIDROCLOROTIAZIDA CAPSULASRipasudil
go.drugbank.com/drugs/DB13165InvestigationalIt was first approved for treatment in Japan in September 2014. This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec. … Ripasudil, as hydrochloride hydrate (K-115), is a specifc Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor used for the treatment of glaucoma and ocular hypertension.
Categories: Sympathomimetics in Glaucoma TherapyButyrfentanyl
go.drugbank.com/drugs/DB09173ExperimentalIllicit[A182054] It is an analog of [fentanyl] with roughly 1/30 the potency.[L7811] Butyrfentanyl was first synthesized in 1961 by Janssen Pharmaceuticals as a new opioid analgesic. … [L7811] Butyrfentanyl has no current legitimate clinical applications, but anecdotal reports indicate it may occasionally be surfacing on the grey-market as a recreational drug.
Etilefrine
go.drugbank.com/drugs/DB08985ApprovedWithdrawnEtilefrine is an adrenergic agonist that appears to interact with beta-1 and some alpha-adrenergic receptors. It has been used as a vasoconstrictor agent.
Categories: Compounds used in a research, industrial, or household settingBelantamab mafodotin
go.drugbank.com/drugs/DB15719ApprovedInvestigationalWithdrawn[L44236] In July of 2025, belantamab mafodotin was approved by Health Canada for a similar indication, but for use in combination with either [Dexamethasone] and [Bortezomib] or [Dexamethasone] and [Pomalidomide … [L53673] Later that year in October of 2025, belantamab was granded full approval by the FDA for the a similar indication to the Health Canada one. [L54331]
Aclidinium
go.drugbank.com/drugs/DB08897ApprovedIt has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012. … Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD).
Enfuvirtide
go.drugbank.com/drugs/DB00109ApprovedInvestigationalThe first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.
Categories: Gene Products, env, env Gene Products, Human Immunodeficiency Virus